364 related articles for article (PubMed ID: 30355266)
1. Long-Acting HIV Drugs for Treatment and Prevention.
Gulick RM; Flexner C
Annu Rev Med; 2019 Jan; 70():137-150. PubMed ID: 30355266
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. Emerging Trends in the Long-Acting Antiretroviral Therapy: Current Status and Therapeutic Challenges.
Labh R; Gupta R
Curr HIV Res; 2021; 19(1):4-13. PubMed ID: 32838720
[TBL] [Abstract][Full Text] [Related]
4. Long-acting drugs and formulations for the treatment and prevention of HIV infection.
Flexner C; Owen A; Siccardi M; Swindells S
Int J Antimicrob Agents; 2021 Jan; 57(1):106220. PubMed ID: 33166693
[TBL] [Abstract][Full Text] [Related]
5. Long-acting injectable antiretrovirals for HIV treatment and prevention.
Spreen WR; Margolis DA; Pottage JC
Curr Opin HIV AIDS; 2013 Nov; 8(6):565-71. PubMed ID: 24100877
[TBL] [Abstract][Full Text] [Related]
6. Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis.
Flexner C; Thomas DL; Swindells S
Curr Opin HIV AIDS; 2019 Jan; 14(1):13-20. PubMed ID: 30394948
[TBL] [Abstract][Full Text] [Related]
7. Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection.
Ullah Nayan M; Sillman B; Hasan M; Deodhar S; Das S; Sultana A; Thai Hoang Le N; Soriano V; Edagwa B; Gendelman HE
Adv Drug Deliv Rev; 2023 Sep; 200():115009. PubMed ID: 37451501
[TBL] [Abstract][Full Text] [Related]
8. Cabotegravir long-acting for HIV-1 prevention.
Andrews CD; Heneine W
Curr Opin HIV AIDS; 2015 Jul; 10(4):258-63. PubMed ID: 26049951
[TBL] [Abstract][Full Text] [Related]
9. Long-acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient's perspective.
Rusconi S; Marcotullio S; Cingolani A
New Microbiol; 2017 Apr; 40(2):75-79. PubMed ID: 28368071
[TBL] [Abstract][Full Text] [Related]
10. Regulatory challenges in developing long-acting antiretrovirals for treatment and prevention of HIV infection.
Arya V; Au S; Belew Y; Miele P; Struble K
Curr Opin HIV AIDS; 2015 Jul; 10(4):278-81. PubMed ID: 26049954
[TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
12. Universal antiretroviral regimens: thinking beyond one-pill-once-a-day.
Jacobson JM; Flexner CW
Curr Opin HIV AIDS; 2017 Jul; 12(4):343-350. PubMed ID: 28368868
[TBL] [Abstract][Full Text] [Related]
13. Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention.
Barrett SE; Teller RS; Forster SP; Li L; Mackey MA; Skomski D; Yang Z; Fillgrove KL; Doto GJ; Wood SL; Lebron J; Grobler JA; Sanchez RI; Liu Z; Lu B; Niu T; Sun L; Gindy ME
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012772
[TBL] [Abstract][Full Text] [Related]
14. Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.
Lykins WR; Luecke E; Johengen D; van der Straten A; Desai TA
Drug Deliv Transl Res; 2017 Dec; 7(6):805-816. PubMed ID: 28612340
[TBL] [Abstract][Full Text] [Related]
15. A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.
Kovarova M; Swanson MD; Sanchez RI; Baker CE; Steve J; Spagnuolo RA; Howell BJ; Hazuda DJ; Garcia JV
J Antimicrob Chemother; 2016 Jun; 71(6):1586-96. PubMed ID: 27002074
[TBL] [Abstract][Full Text] [Related]
16. Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.
Nelson AG; Zhang X; Ganapathi U; Szekely Z; Flexner CW; Owen A; Sinko PJ
J Control Release; 2015 Dec; 219():669-680. PubMed ID: 26315816
[TBL] [Abstract][Full Text] [Related]
17. The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review.
Hankins CA; Dybul MR
Curr Opin HIV AIDS; 2013 Jan; 8(1):50-8. PubMed ID: 23201856
[TBL] [Abstract][Full Text] [Related]
18. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned.
Friend DR; Kiser PF
Antiviral Res; 2013 Sep; 99(3):391-400. PubMed ID: 23845918
[TBL] [Abstract][Full Text] [Related]
19. Combination therapies currently under investigation in phase I and phase II clinical trials for HIV-1.
Pham HT; Yoo S; Mesplède T
Expert Opin Investig Drugs; 2020 Mar; 29(3):273-283. PubMed ID: 31994943
[No Abstract] [Full Text] [Related]
20. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
Özdener AE; Park TE; Kalabalik J; Gupta R
Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
